All Pharma News
Remember that record biotech IPO party in 2018? no ‘happily ever after’

Remember that record biotech IPO party in 2018? no ‘happily ever after’
ENDPTS
08 May 2023
Share Share
Aptinyx evaluates future of the company following two failed trials, 60% layoffs

Aptinyx evaluates future of the company following two failed trials, 60% layoffs
Katherine Lewin ENDPTS
31 Mar 2023
Share Share
Aptinyx Reports on 4Q and Full Year 2022 Results

Aptinyx Reports on 4Q and Full Year 2022 Results
BUSINESSWIRE
30 Mar 2023
Share Share
Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop

Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop
Nick Paul Taylor FIERCE BIOTECH
28 Feb 2023
Share Share
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment

Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment
BUSINESSWIRE
27 Feb 2023
Share Share
Aptinyx to Present at the SVB Securities Global Biopharma Conference

Aptinyx to Present at the SVB Securities Global Biopharma Conference
BUSINESSWIRE
31 Jan 2023
Share Share
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented

Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented
BUSINESSWIRE
10 Nov 2022
Share Share
Drugs up for sale, on the shelf in biotech pipeline clear-outs

Drugs up for sale, on the shelf in biotech pipeline clear-outs
Nick Paul Taylor FIERCEBIOTECH
09 Nov 2022
Share Share
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
BUSINESSWIRE
08 Nov 2022
Share Share
Clinical Evaluation of Aptinyx`s NYX-783 to Be Funded by $5.6M NIH Grant

Clinical Evaluation of Aptinyx`s NYX-783 to Be Funded by $5.6M NIH Grant
BUSINESSWIRE
03 Nov 2022
Share Share